Offering new data for Antegren against Crohn's disease, Biogen Idec Inc. said it will file for approval in the European Union but is conducting another study in the U.S. before seeking approval here. (BioWorld Today)

Genta Inc.'s decision to reduce its work force as a way of focusing on the melanoma therapy Genasense, combined with the simultaneous move to withdraw the new drug application for that lead product, "might be confusing from an external perspective," conceded Joy Schmitt, spokeswoman for the company. (BioWorld Today)

Say "Erbitux" to biotechnology investors and you're likely to get a reaction that is definitely...ambivalent. (BioWorld Financial Watch)